This study analyzed 2,493 “real world” patients, 1,352 receiving the Evolut R/Pro, 675 the SAPIEN, 3,270 the Acurate Neo and 192 the Portico.
Primary end point was all cause mortality and major adverse cardiovascular events (MACE) at 5 years.
Populations were similar, with EuroSCORE 4.9%, and there were no significant differences in comorbidities or echocardiographic parameters.
At 5 years, there were no differences in primary end point, neither were there any differences in all-cause mortality, stroke, MI or need for valve reintervention.
It was also observed that patients receiving the SAPIEN 3 saw fewer hospitalizations for cardiac failure vs. the rest of patients.
Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.
Original Title: Long-term multiple comparison of transcatheter aortic valves – insights from the OBSERVANT II study.
Reference: Giuliano Costa.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
